INDOCOPharmaceuticals
Indoco Remedies Ltd — Profit & Loss Statement
₹164.00
-6.69%
Indoco Remedies Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.30 Cr | 3.29 Cr | -0.34 Cr | -1.27 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.29 | 0.26 | 0.35 | — |
| Normalized EBITDA | 104.71 Cr | 254.16 Cr | 288.46 Cr | 333.90 Cr | — |
| Total Unusual Items | 0.99 Cr | 11.53 Cr | -1.31 Cr | -3.66 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.99 Cr | 11.53 Cr | -1.31 Cr | -3.66 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -73.74 Cr | 98.47 Cr | 142.25 Cr | 154.80 Cr | — |
| Reconciled Depreciation | 98.25 Cr | 87.98 Cr | 70.61 Cr | 77.20 Cr | — |
| Reconciled Cost Of Revenue | 498.18 Cr | 559.19 Cr | 539.31 Cr | 479.60 Cr | — |
| EBITDA | 105.70 Cr | 265.69 Cr | 287.15 Cr | 330.24 Cr | — |
| EBIT | -8.14 Cr | 173.82 Cr | 216.54 Cr | 253.03 Cr | — |
| Net Interest Income | -66.23 Cr | -38.02 Cr | -24.69 Cr | -16.96 Cr | — |
| Interest Expense | 66.23 Cr | 38.02 Cr | 23.75 Cr | 16.46 Cr | — |
| Normalized Income | -74.43 Cr | 90.23 Cr | 143.22 Cr | 157.19 Cr | — |
| Net Income From Continuing And Discontinued Operation | -73.74 Cr | 98.47 Cr | 142.25 Cr | 154.80 Cr | — |
| Total Expenses | 1.66K Cr | 1.64K Cr | 1.44K Cr | 1.28K Cr | — |
| Diluted EPS | -8.46 | 10.51 | 15.42 | 16.80 | — |
| Gross Profit | 1.14K Cr | 1.23K Cr | 1.10K Cr | 1.02K Cr | — |
| Cost Of Revenue | 498.18 Cr | 559.19 Cr | 539.31 Cr | 479.60 Cr | — |
| Total Revenue | 1.64K Cr | 1.79K Cr | 1.64K Cr | 1.50K Cr | — |
| Operating Revenue | 1.64K Cr | 1.79K Cr | 1.64K Cr | 1.50K Cr | — |
| Diluted Average Shares | 8.72 Cr | 9.37 Cr | 9.22 Cr | 9.22 Cr | — |
| Basic Average Shares | 8.72 Cr | 9.35 Cr | 9.22 Cr | 9.22 Cr | — |
| Basic EPS | -8.46 | 10.53 | 15.44 | 16.80 | — |
| Diluted NI Availto Com Stockholders | -73.74 Cr | 98.47 Cr | 142.25 Cr | 154.80 Cr | — |
| Net Income Common Stockholders | -73.74 Cr | 98.47 Cr | 142.25 Cr | 154.80 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -73.74 Cr | 98.47 Cr | 142.25 Cr | 154.80 Cr | — |
| Minority Interests | 4.21 Cr | 1.46 Cr | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | -77.95 Cr | 97.01 Cr | 142.25 Cr | 154.80 Cr | — |
| Net Income Continuous Operations | -77.95 Cr | 97.01 Cr | 142.25 Cr | 154.80 Cr | — |
| Tax Provision | 3.58 Cr | 38.79 Cr | 50.54 Cr | 81.77 Cr | — |
| Pretax Income | -74.37 Cr | 135.80 Cr | 192.79 Cr | 236.57 Cr | — |
| Other Non Operating Income Expenses | 5.45 Cr | 9.85 Cr | 0.38 Cr | 0.47 Cr | — |
| Special Income Charges | 0.99 Cr | 11.53 Cr | -1.31 Cr | -3.66 Cr | — |
| Restructuring And Mergern Acquisition | -0.99 Cr | -11.53 Cr | 0.00 | — | — |
| Net Non Operating Interest Income Expense | -66.23 Cr | -38.02 Cr | -24.69 Cr | -16.96 Cr | — |
| Interest Expense Non Operating | 66.23 Cr | 38.02 Cr | 23.75 Cr | 16.46 Cr | — |
| Operating Income | -14.58 Cr | 152.44 Cr | 197.64 Cr | 220.23 Cr | — |
| Operating Expense | 1.16K Cr | 1.08K Cr | 903.10 Cr | 803.91 Cr | — |
| Other Operating Expenses | 597.42 Cr | 554.70 Cr | 262.40 Cr | 216.73 Cr | — |
| Depreciation And Amortization In Income Statement | 113.84 Cr | 91.87 Cr | 70.61 Cr | 77.21 Cr | — |
| Depreciation Income Statement | 113.84 Cr | 91.87 Cr | 56.36 Cr | 50.77 Cr | — |
| Research And Development | 76.01 Cr | 97.16 Cr | 80.97 Cr | 74.64 Cr | — |
| Selling And Marketing Expense | — | 175.12 Cr | 141.22 Cr | 117.26 Cr | 112.10 Cr |
| General And Administrative Expense | — | 36.76 Cr | 25.63 Cr | 19.65 Cr | 16.73 Cr |
| Rent And Landing Fees | — | 8.23 Cr | 7.44 Cr | 5.67 Cr | 5.00 Cr |
| Interest Income | — | 3.96 Cr | 0.58 Cr | 0.47 Cr | 0.79 Cr |
| Rent Expense Supplemental | — | 8.23 Cr | 7.44 Cr | 5.67 Cr | 5.00 Cr |
| Other Special Charges | — | 0.38 Cr | 1.26 Cr | 0.51 Cr | 0.24 Cr |
| Impairment Of Capital Assets | — | 8.11 Cr | 0.05 Cr | 3.15 Cr | 16.53 Cr |
| Total Other Finance Cost | — | 1.93 Cr | 1.52 Cr | 0.97 Cr | 1.06 Cr |
| Interest Income Non Operating | — | 3.96 Cr | 0.58 Cr | 0.47 Cr | 0.79 Cr |
| Amortization | — | 29.41 Cr | 14.24 Cr | 26.44 Cr | 23.38 Cr |
| Selling General And Administration | — | 211.88 Cr | 166.85 Cr | 136.91 Cr | 128.83 Cr |
| Write Off | — | — | — | -1.36 Cr | -1.68 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Indoco Remedies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.